Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alere Challenges Medicare Billing Block

Executive Summary

The company, which had its Medicare supplier billing number revoked in November, filed an appeal with an administrative law judge. Alere also asked the US District Court for the District of Columbia to force CMS to allow its Arriva unit to stay in the competitive bidding program while the ALJ appeal is pending.

You may also be interested in...



US Joins FCA Case Against Alere Unit

Alere subsidiary Arriva Medical routinely gave Medicare beneficiaries glucometers they didn’t need and billed the government for them, a recently unsealed lawsuit claims.

EU Approves Troubled Abbott-Alere Deal – But Abbott Still Wants Out

The European Commission has approved Abbott Laboratories' pending acquisition of Alere, on condition that Alere's Epoc, Triage and BNP businesses are divested to alleviate anti-trust concerns. However, Abbott is still looking to cut loose from the $5.8bn deal.

Abbott Steps Up Effort To Abandon Alere Deal

Abbott has asked a Delaware court to cancel its agreement to buy Alere for $5.8bn based on a series of financial and regulatory missteps by Alere. Alere, which earlier sued to force the merger to go through, plans to fight the suit.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT104256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel